10,360 Shares in Insulet Corporation $PODD Purchased by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Insulet Corporation (NASDAQ:PODD) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 10,360 shares of the medical instruments supplier’s stock, valued at approximately $1,577,000.

A number of other institutional investors have also recently bought and sold shares of PODD. Vancity Investment Management Ltd increased its holdings in shares of Insulet by 34.6% during the second quarter. Vancity Investment Management Ltd now owns 2,866 shares of the medical instruments supplier’s stock worth $436,000 after purchasing an additional 737 shares during the period. California State Teachers Retirement System boosted its stake in shares of Insulet by 13,901.9% in the second quarter. California State Teachers Retirement System now owns 14,562,256 shares of the medical instruments supplier’s stock valued at $2,217,103,000 after buying an additional 14,458,254 shares during the period. HB Wealth Management LLC grew its position in Insulet by 33.4% during the second quarter. HB Wealth Management LLC now owns 4,298 shares of the medical instruments supplier’s stock worth $654,000 after buying an additional 1,077 shares in the last quarter. Saudi Central Bank grew its position in Insulet by 86.7% during the second quarter. Saudi Central Bank now owns 4,849 shares of the medical instruments supplier’s stock worth $738,000 after buying an additional 2,252 shares in the last quarter. Finally, Angeles Wealth Management LLC increased its stake in Insulet by 36.8% during the 2nd quarter. Angeles Wealth Management LLC now owns 3,728 shares of the medical instruments supplier’s stock worth $568,000 after acquiring an additional 1,003 shares during the period.

Insulet Stock Down 2.0%

Shares of PODD opened at $131.96 on Friday. The firm has a 50 day simple moving average of $152.36 and a two-hundred day simple moving average of $173.92. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The company has a market cap of $9.15 billion, a P/E ratio of 24.67, a P/E/G ratio of 1.06 and a beta of 1.08.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter last year, the business posted $1.17 EPS. The company’s revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts forecast that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PODD shares. UBS Group dropped their price objective on Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a report on Thursday, August 6th. Leerink Partners lowered Insulet from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $247.00 to $145.00 in a report on Thursday, August 6th. Sanford C. Bernstein decreased their price target on Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Oppenheimer downgraded Insulet from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 5th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $205.00 price objective on shares of Insulet in a research report on Wednesday, May 27th. Fourteen investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $195.40.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.